戻る Agenda
Session 3: The Future of Pharmacovigilance
Session Chair(s)
Wendy Huisman, PharmD
Director
Vigifit, Netherlands
In this session we will focus on the nest steps in Pharmacovigilance. What will the future bring us? Where do we need new standards and where do we want to remove strict guidance? What is there to keep and what will be gone in 10 years? How far are we with automation and AI?
Speaker(s)
Are New Standards Needed? A Regulator’s Perspective
Sabine Straus, MD, PhD, MSc
Medicines Evaluation Board (MEB), Netherlands
PRAC Chair, Staff Member
Evolving Safety: Value Provider, or Pure Necessity?
Sergio Ley-Acosta, MD
Genentech, United States
Global Head Portfolio Clinical Safety
A.I. in Pharmacovigilance: Where Are We?
Patrick M. Caubel, MD, PhD, MBA
Pfizer Inc, United States
Chief Safety Officer
Visionary Approach to PV. Industry Perspective.
Wendy Huisman, PharmD
Vigifit, Netherlands
Director